Like last year in New York, Drugs for Neglected Diseases initiative (DNDi) will bring together more than 150 scientists, researchers, academics and global health leaders from Africa, Asia, Europe, Latin America and North America on June 23, 2009, to discuss how international research partnerships can best develop and deliver new lifesaving drugs for neglected diseases.
This daylong meeting will bring together DNDi’s key partners in funding, private industry, and public institutions. As the event is hosted by DNDi Africa, DNDi expects many researchers and clinicians from endemic countries to attend, especially from Africa. These leading experts will have the opportunity to examine ongoing DNDi projects in drug research and development, access, and capacity strengthening.
This event will be an excellent forum to share knowledge on the realities of conducting research, managing drug development, ensuring access to treatment, and securing funding for neglected diseases.
Agenda
If you would like to download the full Agenda, please click here.
Programme
If you would like to download the full Programme, please click here.
Press Releases
Session 1: DNDi Strategy
1. DNDi Update: Global Partnership Addressing Needs of Most Neglected – From Research Through Access
by Bernard Pécoul, Shing Chang & Monique Wasunna, DNDi
Session 2: Delivering Innovation to Patients: On-the-Ground Access Challenges
2. Human African Trypanosomiasis: Conducting quality trials in resource-poor settings [Français]
by Wilfried Mutombo, PNLTHA Kasaï Oriental (DRC)
3. Leishmaniasis East African Platform (LEAP): Preparing the field for implementation
by Ahmed Musa Mudawi, University of Khartoum (Sudan)
4. Improving Access to ACTs via Home-Based Management?
by Ambrose Talisuna, MMV (Uganda)
Session 3: Enabling a Favorable R&D Environment in Africa
5. How innovative mechanisms contribute to scaling up access to treatments and establishing new mechanisms to boost innovation for neglected diseases
by Jorge Bermudez, UNITAID
6. Role of a donor in strengthening research capacity in disease-endemic countries and ensuring sustainable funding for most neglected diseases
by Jo Mulligan, DFID (UK)
7. Adapting approval mechanisms to new NTD drugs
by Javier Guzman, MBBS, MSc, Director of Research, The George Institute, on behalf of Mary Moran, MD, Director, Health Policy Division, The George Institute (Australia)
Panelists:
8. Charles Mazinda, ASAQ study (Liberia)
9. George W. Baguma, Quality Chemicals Ltd (Uganda)
10. John Amuasi (Ghana)
Session 4: Keynote Addresses
11. Ogobara Doumbo, Malaria Research and Training Center (Mali)
12. Carlos Morel, Oswaldo Cruz Foundation, Fiocruz; member, DNDi Board (Brazil)
Press Releases
If you would like to read the Press Release, please click here.
Videos
Partnership of the Year: LEAP (Leishmaniasis East Africa Platform)
If you would like to watch the video about this platform conducting clinical trials to develop new and more adapted treatments to treat visceral leishmaniasis, please click here.
Project of the Year: NECT for Sleeping Sickness (Nifurtimox-Eflornithine Combination Therapy)
If you lwould ike to watch the video about the improved treatment NECT for sleeping sickness (human African trypanosomiasis, or HAT), which is now included into the Essential Medicines List (EML) of WHO, an English version and a French version are available.
Press Articles
BMJ, Collaborations aim to develop new drugs for neglected tropical diseases
by Janice Hopkins Tanne, June 29, 2009
IPS, HEALTH-AFRICA: Neglected Diseases Under the Microscope
by Joyce Mulama, June 17, 2009
